Routine cognitive screening in a neurology practice: Effect on physician behavior

Background:Alzheimer disease is one of the most prevalent and costly neurologic disorders. American Academy of Neurology guidelines call for diagnosis and treatment when dementia is present, but provide no specific instruction relating to cognitive screening. Methods:Our center piloted a cognitive screening initiative using the Mini-Cog, which was administered to all neurology patients aged ≥70 years without a history of a cognitive disorder. Results:There was a 37.4% screen positive rate on the Mini-Cog. The percentage of patients with subjective memory complaints did not differ between patients screening positive vs negative on the Mini-Cog. Prospective analysis over an 18-month postscreening period showed that individuals screening positive for cognitive impairment were 10 times more likely to have follow-up cognitive assessment by the provider (p < 0.0001), almost 3 times more likely to be referred for neuropsychological testing (p = 0.003), and 3 times more likely to receive a diagnosis of cognitive impairment or dementia (p < 0.0001) compared to those screening negative. Diagnosis of a cognitive disorder, referral to a cognitive specialty clinician, and prescription of cognitive-enhancing medications were no more frequent than was observed in a randomized trial of screening in primary care, and evidence of neurologists' actions relevant to cognitive impairment was found in a minority of individuals screening positive. Conclusion:Further studies are needed to better understand factors influencing neurologist actions in the evaluation and treatment of cognitive impairment.

[1]  K. Tsoi,et al.  Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. , 2015, JAMA internal medicine.

[2]  B. Dickerson Dysfunction of Social Cognition and Behavior , 2015, Continuum.

[3]  R. Albin,et al.  Factors associated with cognitive evaluations in the United States , 2015, Neurology.

[4]  Elizabeth Eckstrom,et al.  Screening for Cognitive Impairment in Older Adults: A Systematic Review for the U.S. Preventive Services Task Force , 2013, Annals of Internal Medicine.

[5]  Zhou Yang,et al.  Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.

[6]  J. McCarten,et al.  Screening for Cognitive Impairment in an Elderly Veteran Population: Acceptability and Results Using Different Versions of the Mini‐Cog , 2011, Journal of the American Geriatrics Society.

[7]  Henry Brodaty,et al.  Management of behavioral problems in Alzheimer's disease , 2010, International Psychogeriatrics.

[8]  David L. Weimer,et al.  Early identification and treatment of Alzheimer's disease: Social and fiscal outcomes , 2009, Alzheimer's & Dementia.

[9]  Jeffrey Hummel,et al.  Implementing Routine Cognitive Screening of Older Adults in Primary Care: Process and Impact on Physician Behavior , 2007, Journal of General Internal Medicine.

[10]  Peijun Chen,et al.  The Mini‐Cog as a Screen for Dementia: Validation in a Population‐Based Sample , 2003, Journal of the American Geriatrics Society.

[11]  B. Miller,et al.  CME Practice parameter : Diagnosis of dementia ( an evidence-based review ) Report of the Quality Standards Subcommittee of the American Academy of Neurology , 2001 .

[12]  S. Borson,et al.  The Mini‐Cog: a cognitive ‘vital signs’ measure for dementia screening in multi‐lingual elderly , 2000, International journal of geriatric psychiatry.

[13]  K. Davis Cholinesterase Inhibitors in Alzheimer's Disease , 1994, Neuropsychopharmacology.

[14]  Paco Martorell,et al.  Monetary costs of dementia in the United States. , 2013, The New England journal of medicine.

[15]  J. Morris,et al.  Cholinesterase Inhibitors for Alzheimer’s Disease , 2012, Drugs.